INI-822 treatment alters plasma levels of hydroxy-lipid substrates of HSD17B13
June 23, 2023
Researchers from Inipharm Inc. presented preclinical data for INI-822, a small-molecule inhibitor of HSD17B13, being developed for the treatment of liver disease.